427.50
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $427.50, with a volume of 3.04M.
It is down -2.13% in the last 24 hours and down -17.72% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
See More
Previous Close:
$436.79
Open:
$434.54
24h Volume:
3.04M
Relative Volume:
1.49
Market Cap:
$169.62B
Revenue:
$42.88B
Net Income/Loss:
$6.34B
P/E Ratio:
25.86
EPS:
16.53
Net Cash Flow:
$7.27B
1W Performance:
+0.01%
1M Performance:
-17.72%
6M Performance:
-28.66%
1Y Performance:
-21.88%
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
![]()
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
Dec-23-24 | Initiated | Scotiabank | Sector Perform |
Oct-14-24 | Initiated | Redburn Atlantic | Buy |
Oct-01-24 | Initiated | Stephens | Overweight |
Aug-28-24 | Initiated | Wells Fargo | Overweight |
Jun-03-24 | Resumed | Jefferies | Buy |
Mar-18-24 | Resumed | Citigroup | Neutral |
Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Sep-28-23 | Initiated | Bernstein | Outperform |
Sep-06-23 | Resumed | Citigroup | Buy |
Jul-19-23 | Initiated | Raymond James | Outperform |
Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
Apr-04-23 | Reiterated | Barclays | Overweight |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Jan-26-22 | Resumed | Barclays | Overweight |
Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jul-16-21 | Initiated | The Benchmark Company | Buy |
Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-03-21 | Initiated | Barclays | Overweight |
Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-02-20 | Initiated | Goldman | Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Sep-14-20 | Initiated | Morgan Stanley | Overweight |
Aug-20-20 | Resumed | JP Morgan | Overweight |
Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
Jul-07-20 | Reiterated | Needham | Buy |
Apr-23-20 | Reiterated | Needham | Buy |
Jan-31-20 | Reiterated | Needham | Buy |
Jan-22-20 | Initiated | Credit Suisse | Neutral |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Buy |
Nov-15-19 | Initiated | Stifel | Buy |
Jul-25-19 | Reiterated | Needham | Buy |
Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
May-30-19 | Initiated | Wolfe Research | Outperform |
May-23-19 | Reiterated | Needham | Strong Buy |
Apr-22-19 | Reiterated | Needham | Strong Buy |
Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Is Thermo Fisher Scientific Inc. (TMO) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
Drug Abuse Testing Market Forecast Report and Company - GlobeNewswire
NMR Spectroscopy Market to Hit USD 2.08 Billion by 2032, Fueled by Pharmaceutical R&D and Rising Demand for Molecular Structure Analysis | SNS Insider - GlobeNewswire Inc.
Biochips Market Set to Witness Significant Growth by 2023 | - openPR.com
Thermo Fisher opens collaboration centre in US to help accelerate cell therapy development - BioSpectrum Asia
Assessing Thermo Fisher Scientific: Insights From 9 Financial Analysts - Benzinga
Thermo Fisher swaps HFCs for natural refrigerants in new large‑capacity and superspeed centrifuges - R&D World
Thermo Fisher Scientific Inc. (TMO): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
Theranostics Market Growth Analysis and Forecast 2025-2032 | - openPR.com
Leerink Adjusts Price Target on Thermo Fisher Scientific to $625 From $640, Maintains Outperform Rating - MarketScreener
Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development - Bakersfield.com
Lobbying Update: $1,450,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Nasdaq
Thermo Fisher Scientific named founding sponsor of LifeSciNKY - LINK nky
10 manufacturing acquisitions to know from Q1 - Manufacturing Dive
Bernstein Cuts Price Target on Thermo Fisher Scientific to $585 From $690, Keeps Outperform Rating - MarketScreener
Baird Cuts Price Target on Thermo Fisher Scientific to $603 From $660, Keeps Outperform Rating - MarketScreener
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Next Generation Sequencing Market on the Rise: Applications & - openPR.com
Thermo Fisher stock gains after Sartorius Q1 results (TMO) - Seeking Alpha
Robust Specialty Diagnostics Segment Likely to Aid TMO's Q1 Earnings - TradingView
Thermo Fisher Scientific Introduces the 5L DynaDrive Single-Use Bioreactor - Technology Networks
Northern Kentucky-based LifeSciKY announces Thermo Fisher Scientific as founding sponsor - Northern Kentucky Tribune
Thermo Fisher Scientific - WACH
LifeSciKY inks partnership with Thermo Fisher Scientific as Founding Sponsor - Yahoo Finance
Thermo Fisher Scientific Introduces the 5L DynaDrive Single-Use Bioreactor to Simplify and Accelerate Process Development and Help Bring Therapies to Market Faster - MSN
Thermo Fisher acquires Solventum’s PF business in $4.1bn deal - Financier Worldwide
Thermo Fisher Scientific Stock Up 1.3% After Key Signal - Benzinga
Sickle Cell Anemia Testing and Screening Market Detailed In New - openPR.com
Thermo Fisher Scientific launches bench scale bioreactor enabling productivity, scalability and efficiency - BioSpectrum Asia
3d Cell Culture Market Set to Witness Significant Growth - openPR.com
Thermo Fisher Scientific (NYSE:TMO) Launches 5L DynaDrive Bioreactor To Enhance Bioprocessing - simplywall.st
Thermo Fisher Scientific And Its Real Value (NYSE:TMO) - Seeking Alpha
BofA Securities Cuts Price Target on Thermo Fisher Scientific to $545 From $680, Keeps Buy Rating - MarketScreener
Helicobacter Pylori Diagnostics Market Is Booming Worldwide | Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc. - openPR.com
Thermo Fisher Scientific Introduces 5L DynaDrive Single-Use Bioreactor - Contract Pharma
SPONSORED Boys & Girls Clubs and Thermo Fisher Scientific fuel the future of STEM - Axios
Why Thermo Fisher Scientific (TMO) Is One of the Best Medical Stocks to Buy According to Billionaires - Insider Monkey
Bernstein maintains Thermo Fisher stock with $690 target - Investing.com
Ultrasonic Aspirator Market Poised for Rapid Growth, Expected - openPR.com
Nucleic Acid Isolation And Purification Market Generated - openPR.com
Thermo Fisher Scientific Inc (TMO) Trading Down 6.22% on Apr 10 - GuruFocus
Meningitis Diagnostic Testing Market Deep Research Report with - openPR.com
The Zacks Analyst Blog Highlights Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri - Yahoo Finance
Escherichia Coli Strain Market to Witness Remarkable Growth - openPR.com
Nanorobotics Market Set to Witness Significant Growth - openPR.com
Top Research Reports for Eli Lilly, American Express & Thermo Fisher - Yahoo Finance
Barclays Adjusts Price Target on Thermo Fisher Scientific to $475 From $620 - MarketScreener
Assisted Reproductive Technology Market Forecast Report and Company Analysis 2025-2033 Featuring Thermo Fisher Scientific, Sumitomo Mitsui, CooperSurgical, Fujifilm, Merck, Progyny, Cosmos BiomedicalResearchAndMarkets.com - Bluefield Daily Telegraph
gRNA Market Top Companies StudyThermo Fisher Scientific Inc., - openPR.com
Thermo Fisher (TMO) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):